OncoMatch/Clinical Trials/NCT06150898
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
Is NCT06150898 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ketorolac 10 Mg Oral Tablet and Pregabalin 75mg for early-stage breast cancer.
Treatment: Ketorolac 10 Mg Oral Tablet · Pregabalin 75mg · Omeprazole 20mg Capsule — Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (IHC ≥ 1% and/or Allred score ≥ 3)
estrogen receptor positive as per ... guidelines ... ER-positive is defined as having an immunohistochemistry (IHC) of 1% or more and/or Allred score of 3 or more
Disease stage
Required: Stage I, II, III
Performance status
ASA 0–2
Demographics
Prior therapy
Cannot have received: neoadjuvant therapy
Neoadjuvant BC therapy
Lab requirements
Blood counts
platelet count ≥ 100,000/μL; absolute neutrophil count ≥ 1000/μL
Kidney function
GFR ≥ 90 ml/min/1.73m² and serum creatinine ≤ 442 μmol/l (≤ 5 mg/dL); no single kidney or previous renal surgery
Liver function
total serum bilirubin < 2 x ULN (unless Gilbert syndrome); ALT < 2 x ULN; ALP < 2.5 x ULN
Inadequate liver function (defined as total serum bilirubin ≥ 2 x upper limit of normal (ULN<1.2 mg/dl) - unless documented Gilbert syndrome- AND Alanine Aminotransferase (ALT) ≥ 2 x ULN (ULN <32 UI/l and ULN <33 UI/l, respectively) AND Alkaline phosphatase (ALP) ≥ 2.5 x ULN (ULN=104 UI/l)); Renal impairment (defined as GFR<90ml/min/1.73m² or serum creatinine > 442 μmol/l or > 5 mg/dL) or single kidney or previous renal surgery; Inadequate bone marrow function (defined as absolute neutrophil count <1000/μL and platelet count <100'000/μL)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06150898 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages